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Microglia are the primary resident immune cells of the central nervous system that
maintain physiological homeostasis in the brain and contribute to the pathogenesis
of many psychiatric disorders and neurodegenerative diseases. Due to the lack of
appropriate human cellular models, it is difficult to study the basic pathophysiological
processes linking microglia to brain diseases. In this study, we adopted a microglia-like
cellular model derived from peripheral blood monocytes with granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-34 (IL-34). We characterized and
validated this in vitro cellular model by morphology, immunocytochemistry, gene
expression profiles, and functional study. Our results indicated that the iMG cells
developed typical microglial ramified morphology, expressed microglial specific surface
markers (P2RY12 and TMEM119), and possessed phagocytic activity. Principal
component analyses and multidimensional scaling analyses of RNA-seq data showed
that iMG cells were distinct from monocytes and induced macrophages (iMacs) but
clustered closer to human microglia and hiPSC-induced microglia. Heatmap analyses
also found that iMG cells, but not monocytes, were closely clustered with human primary
microglia. Further pathway and relative expression analysis indicated that unique genes
from iMG cells were involved in the regulation of the complement system, especially
in the synapse and ion transport. Overall, our data demonstrated that the iMG model
mimicked many features of the brain resident microglia, highlighting its utility in the study
of microglial function in many brain diseases, such as schizophrenia and Alzheimer’s
disease (AD).
Keywords: induced microglia-like cells (iMG cells), RNA-seq profile, peripheral blood mononuclear cells,
phagocytosis, schizophrenia, Alzheimer’s disease, synaptic pruning
INTRODUCTION
Microglia are the primary immune cells of the central nervous system (CNS) that belong
to the myeloid lineage. The origins of microglia and their functions in the CNS have
been extensively debated since they were first described by Pio del Rio-Hortega in 1932
(Río-Hortega, 1932). In the mouse brain, microglia originate from myeloid progenitors in
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the yolk sac that migrate to the brain during early embryonic
stages before the blood-brain barrier is formed (Ginhoux et al.,
2013). A similar pattern of events may occur in humans, but
under certain inflammatory conditions, the recruitment of bone
marrow-derived progenitors may supplement the microglial
population to some extent (Ginhoux and Prinz, 2015). The
origins of human microglia are more heterogeneous, with one
population from myeloid/mesenchymal origin in the yolk sac
and a second population representing a developmental and
transitory form of fetal macrophage (possibly monocytes).
During normal brain development, microglia proliferate
and self-renew continually throughout life to maintain cell
numbers, without any contribution from bone marrow-derived
macrophages (Elmore et al., 2014). Microglia serve a variety
of important functions, including immune surveillance,
neurogenesis, synaptic pruning, and phagocytosis (Stansley et al.,
2012). Microglia-mediated synaptic loss by phagocytosis strongly
correlates with cognitive decline in patients with schizophrenia
or AD.
In response to environmental stimuli/stresses, microglia
are highly plastic and can be activated into two distinctive
phenotypes, the classical pro-inflammatory state (M1) and the
alternative anti-inflammatory state (M2) (Ma et al., 2017).
Microglial activation and neuroinflammation are hallmarks
of many CNS pathologies. In response to lipopolysaccharide
(LPS) and interferon (IFN)-γ, microglia are activated to pro-
inflammatory M1 state and release cytokines, such as Interleukin
(IL)-1β, IL-6, Tumor Necrosis Factor (TNF)-α, and neurotoxic
factors. Prolonged hyperactivity of microglia may lead to
neuronal apoptosis and brain damage, as seen in schizophrenia
(Pérez-Neri et al., 2006; Monji et al., 2013) and AD (Akiyama
et al., 2000; Heneka et al., 2015; Wang et al., 2015). Alternatively,
in response to IL-4, microglia can be activated to the M2
state and release numerous anti-inflammatory factors, including
CD206 and IL-10. M2 microglia promote healing and improve
phagocytic capabilities (Cherry et al., 2014).
It is noteworthy that many studies have utilized a mouse
model to investigate microglial phenotypes and functions.
However, microglial transcriptomic signatures vary between
mice and humans (Deczkowska et al., 2018; Friedman et al., 2018;
Zhou et al., 2020); most animal-based clinical trials have failed
in human diseases, including AD (Franco and Cedazo-Minguez,
2014). Other common approaches to study microglia in human
diseases include post-mortem examination of the brain or brain
imaging from living patients. Nevertheless, in vitro studies on
human primary microglia are challenging due to technical and
ethical issues. Human microglial cell lines, such as HMO6 cells
(Nagai et al., 2005) and HMC3 cells (Janabi et al., 1995), can
be an alternative model for human microglia. However, these
cell lines have limited capacity in capturing disease- or patient-
specific features of microglia. Furthermore, cell lines may change
their cellular phenotypes and functions over time due to genetic
manipulations and multiple passages.
Recently, many researchers are experimenting with different
reprogrammingmethods to generate human induced pluripotent
stem cell (hiPSC)-derived microglia (Muffat et al., 2016; Abud
et al., 2017; Douvaras et al., 2017; Haenseler et al., 2017; Pandya
et al., 2017; Takata et al., 2017). While research on hiPSC-derived
microglia has been shown to be promising, the field still
faces technical challenges, such as long differentiation period,
which may not be suitable for high throughput clinical trials,
especially for AD patients. Therefore, it is urgent to establish an
efficient cellularmodel representing patient-specificmicroglia for
neurological disease studies.
In this study, we generated and modified a human microglial
model, with a 10–14-day conversion from human peripheral
blood monocytes, according to previous studies (Ohgidani
et al., 2014). The main purpose of this study was to validate
the iMG cellular model with morphology, surface markers,
functional assays, and RNA-seq profile. Our goals are (1) establish
and validate a personalized microglia-like model from human
monocytes; (2) develop an in vitro cellular system to study
microglial functions, especially phagocytosis and polarization,
at molecular and gene expression levels; (3) demonstrate a
potential application in psychiatric and neurological diseases,
such as schizophrenia and AD. Our data showed that iMG
cells mimicked human primary microglia with their typical
morphology, surface markers, phagocytic capacity, and plasticity
for polarization. With whole-genome transcript profile, we




PBMCs were purchased from AllCells, LLC (Alameda, CA, USA,
#PB003F and #PB001). Fresh blood was purchased from Gulf
Coast Regional Blood Center. All other reagents were RPMI-1640
without glutamine (vWR, Radnor, PA, USA, #vWRL0106-0500),
RPMI-1640 Glutamax (Life Technologies, Carlsbad, CA), Heat-
inactivated fetal bovine serum (FBS, Endotoxin <1.0 EU/mL,
Rockland Immunochemicals Inc, Pottstown, PA, #FBS-01-
0100), Penicillin-streptomycin (P/S) (Gibco), cell culture plates
(Corning, NY), Geltrex (Thermo Fisher Scientific Waltham,
MA, #A1413202), Trizol (Invitrogen, Carlsbad, CA, #15596018),
SuperScriptTM IV VILOTM Master Mix (Invitrogen, Carlsbad,
CA), High-Capacity cDNAReverse Transcription Kit with RNase
Inhibitor (Thermo Fisher Scientific Waltham, MA, #4374966),
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA),
Phosphate buffer saline (PBS) (Genesee Scientific, San Diego,
CA), Histopaque-1077 (Sigma Chemical Co., St. Louis, MO),
SepMateTM-50 tube (Stem cell technologies), IL-34 (R&D Systems
Minneapolis, MN, #5265-IL-010/CF), GM-CSF (R&D Systems
Minneapolis, MN, #215-GM-010/CF), Lipopolysaccharide (LPS)
(Sigma, St. Louis, MO, #L6529), human IL-4 (Biolegend,
San Diego, CA, #714904), DMSO (Sigma, St. Louis, MO),
Paraformaldehyde (PFA) (Sigma, St. Louis, MO), Fluoromount-
GTM Mounting Medium with DAPI (Invitrogen, Carlsbad,
CA), human HiLyteTM Fluor 488-labeled Aβ protein (1–42)
(Anaspec, #AS-60479-01), and hexafluoroisopropanol (HFIP)
(#H8508, Sigma).
Antibodies
Primary antibodies were anti-TMEM119 (Proteintech, #27585-
1-AP), anti-P2RY12 (Alomone Labs, #APR-020), anti-Iba1
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(Abcam, #ab15690), anti-PU.1 (Abcam, #ab88082), anti-
CX3CR1 (Invitrogen, #PA5-19910), and anti-TREM2 (Abcam,
#ab209814). Conjugated secondary antibodies were Alexa Fluor
488 (#A11034) and Alexa Fluor 594 (#A10036) from Invitrogen
Carlsbad, CA.
Generation of Induced Microglia-Like Cells
(iMG cells) From Monocytes
Human peripheral blood mononuclear cells (PBMCs) were
isolated from fresh blood by density gradient centrifugation
with Histopaque-1077 in SepMateTM-50 tubes. iMG cells were
generated following the previously reported instructions with
some modifications (Ohgidani et al., 2014). Briefly, 1 × 106
cells/ml fresh PBMCs were first resuspended in complete media
(RPMI-1640 containing 10% FBS and 1% P/S) in plates pre-
coated with 2% Geltrex and incubated overnight at 37◦C with
5% CO2. For frozen PBMCs, cells were thawed and washed
with complete media before plating. The next day (Day 0), non-
adherent cells were carefully removed. The adherent monocytes
were cultured with serum-free media (RPMI-1640 Glutamax
supplemented with 0.1µg/ml IL-34, 0.01µg/ml GM-CSF, and
1% P/S) for 10–14 days. For comparison, induced macrophages
(iMacs) were also generated from monocytes by induction with
RPMI-1640 Glutamax media containing 10% FBS, 0.01µg/ml
GM-CSF, and 1% P/S for 7 days. During the induction, we
replaced fresh media every 3–4 days.
Cell Morphology
During the induction, cellular morphology was monitored
with phase-contrast microscopy (Accu-Scope EXI-300, ACCU-
SCOPE Inc., Commack, NY, USA). Images were captured with
an AU-300-HD digital camera (ACCU-SCOPE Inc.) through
CaptaVision PC Imaging Software.
Immunocytochemistry
For immunocytochemistry, iMG cells or iMacs were first fixed
with 4% PFA for 10min and washed thrice with PBS. For
intracellular staining, cells were permeabilized with 0.01% tween
20/PBS for 30min. Cells were then blocked with 5% BSA/PBS for
30min, followed by incubation with primary antibody (RT for
1 h or 4◦C overnight) and then secondary antibody (RT for 1 h
at dark). The primary antibodies used in this study were anti-
P2RY12 (1:200), anti-TREM2 (1:500), anti-CX3CR1 (1:1000),
anti-Iba1 (1:300), anti-PU.1 (1:200), and anti-TMEM119 (1:500)
diluted in blocking solution. Depending on the species of primary
antibodies, 1:500 Alexa Fluor 488- or Fluor 594-conjugated
antibodies were used for staining. Cells were then mounted on
a glass slide with Fluoromount G containing DAPI. Images were
taken with a confocal laser scanning microscope (Nikon A1R)
equipped with the NIS-Elements Advanced Research software.
Exposure settings within each set of experiments were kept
constant for comparison.
Fibrillary Amyloid-Beta (fAβ42) Preparation
and Phagocytosis Assay
The preparation of fibrillary fluorescent Aβ was modified from
the previously described procedure (Stine et al., 2003; Jungbauer
et al., 2009). Briefly, Human HiLyteTM Fluor 488-labeled Aβ
(1–42) was first resuspended as 0.1mM HFIP and left to dry
in a fume hood overnight. The resulting peptide film was
stored (desiccated) at −20◦C for later use. On the day before
the experiment, the films were dissolved in 0.1mM anhydrous
DMSO and sonicated at 22◦C for 10min in a bath sonicator
(Bioruptor Pico sonication device). To form fibrillary amyloid-
beta 42 (fAβ42), the solution was diluted to 100µM in 10mM
HCl with vigorous shaking at 37◦C for 24 h. iMG cells were
incubated with 100 nM fAβ42 in serum-free DMEM/F12 media
at 37◦C for 4 h. Cells were then quenched with 50mM NH4Cl
for 5min and fixed with 4% PFA for 5min at RT. Next,
cells were stained with anti-Iba1 and mounted on a glass
slide with Fluoromount G containing DAPI. Cells without
fAβ42 treatment were used as negative controls for background
setting. Fluorescent images were captured as described in the
previous section.
Phagocytosis assay was also quantitated by flow cytometry
using Sony SH800 (Sony Biotechnology). To this end, cells with
or without fAβ42 incubation were first detached with 10mM
EDTA for 5min and harvested by cell lifter. Cells were then fixed
with 4% PFA and acquired by a flow cytometer using 488 laser
and analyzed by Flowjo software (Tree Star, San Carlos, CA).
Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR) for in vitro Polarization
In this study, we used LPS and IL-4 for in vitro microglial
activation and polarization. On Day 11, LPS (10µg/ml) or IL-
4 (20 ng/ml) were added to the iMG cells and incubated for
24 h at 37◦C with 5% CO2. The next day, cell morphology
was monitored and captured for each group. The total RNA
was isolated using Trizol according to the manufacturer’s
instruction and subjected to cDNA synthesis using SuperScriptTM
IV VILOTM Master Mix. With the following primers, for M1
(TNF-α) and M2 (CD206) gene-specific primers, qRT-PCR was
performed using PowerUp SYBR Green PCRmix. The relative
expression was normalized to the housekeeping control gene
β-actin. Fold changes in mRNA levels between stimulated and
non-stimulated cells were calculated using the 2−(11CT) method.








For RNA-seq, total RNA was extracted from five subjects,
including three monocytes, three iMacs, and four iMG cells,
by RNeasy Mini kit (Qiagen) following the manufacturer’s
instruction. The subjects’ information, including age, sex, etc.,
were described in Supplementary Table 1. RNA quality was
assessed by Agilent 2100 Bioanalyzer. Total RNA with RIN > 8,
200 ng was subjected to cDNA library construction with RNA
Library Prep Kit v2 protocol (Illumina, San Diego, CA). RNA-
seq was performed on the polyadenylated fraction of RNA using
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 April 2021 | Volume 15 | Article 629279
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Illumina NextSeq 500 platform at a depth of more than 20million
reads. FASTQ files from RNA-seq experiments were aligned to
reference 1000 Genomes GRCh37 with STAR v2.5.2a (Dobin
et al., 2013), and quality-controlled bam files were generated by
GATK (v3.7 and v4.beta.2) RNA-seq pipeline (Al-Ars et al., 2020).
Read counts from each transcript were finally collected using
FeatureCounts v1.5.3 (Liao et al., 2014). The whole genome RNA-
seq project PRJNA678841 generated during the current study
in the format of fastq files have been deposited at the National
Center for Biotechnology Information (NCBI) repository (http://
www.ncbi.nlm.nih.gov/bioproject/678841).
Principal Component Analysis (PCA),
Multidimensional Scaling (MDS), and
Hierarchical Clustering Analysis
To determine the uniformity among the cell types, we conducted
PCA using the R package pcaExplorer to perform a simple
overview of the counts from their expression profiles (Marini
and Binder, 2019). To further determine how the iMG cells
resemble the human microglia and hiPSC-induced microglia,
we performed MDS analysis with microglia expression datasets
from Muffat et al. (2016), Gosselin et al. (2017), and Grubman
et al. (2020). Read counts were transformed to fragments per
kilobase of transcript per million mapped reads (FPKM) with the
edgeR v.3.22.3 (Robinson et al., 2010). Data were then normalized
with the removebatcheffect function and rescaled with R scales
package. For MDS calculation, we used cmdscale function in R
stats and magrittr package (Stefan Milton et al., 2020). The MDS
plot was generated with the R ggplot package (Warnes et al.,
2020).
For hierarchical clustering analysis, we started with a
total of 914 non-overlapped microglial signature genes,
including the 881 genes from Gosselin et al.’s study (Gosselin
et al., 2017) and 42 microglial genes from McQuade and
Blurton-Jones’s study (McQuade and Blurton-Jones, 2019) (See
Supplementary Table 2). Variance stabilized transformation
(VST) data obtained from DESeq2 v1.28.1 were used to process
the two datasets (Love et al., 2014). From the 773 overlapped
genes between our data and reference data, we compared the
expression consistency with the formula for consistency scores=
2xy/(x2 + y2)1/2, where x and y represented the fold change (FC)
from monocytes to microglia in the two datasets, respectively.
Genes with consistency scores >0.50 were considered as
consistent genes (312 genes). We then conducted differential
expression analysis DESeq2, as mentioned above. Raw count
data were normalized by the library size and log-transformation.
Differentially expressed genes were estimated using negative
binomial general model statistics. Heatmap analysis was
conducted with the consistent genes that overlapped with the
differentially expressed genes (201 genes). We used Heatmap.2
function in the R ggplot package (Warnes et al., 2020) for the
Heatmap graph.
For Venn analysis, genes with a mean of the normalized
counts >10 were assigned to each cell type. The Venn
diagram for monocytes, iMacs, and iMG cells was generated
according to the website (http://bioinformatics.psb.ugent.be/
webtools/Venn/). For the unique genes obtained from the Venn
diagram in each specific cell type, we further perform the gene
enrichment analysis according to the instruction from Zhou
et al.’s paper (Zhou et al., 2019).
Of particular interest, we further explored the gene regulation
of somemicroglia-specific genes reported inGosselin et al.’s study
(Gosselin et al., 2017) or Ryan et al.’s study (Ryan et al., 2017).
For this purpose, we used R package pcaExplorer to compare
specific gene expression between iMG cells and monocytes from
our sample and the sample from (Gosselin et al., 2017).
Statistical Analyses
Statistical analyses for RT-PCR were conducted with Student’s t-
test or by ANNOVA for comparing more than two groups, and a
p-value ≤0.05 were considered significant.
RESULTS
Morphology of iMG Cells
In this study, we used fresh or frozen PBMCs to generate
human induced microglia-like cells (iMG cells) using a cocktail
of IL-34 (100 ng/ml) and GM-CSF (10 ng/ml) as described
FIGURE 1 | iMG cells and iMacs were induced from human peripheral blood monocytes. Human peripheral blood monocytes were isolated from blood and
stimulated with IL-34 and GM-CSF for microglia-like cells and GM-CSF only for macrophages. Representative images (A) monocytes after adherence without any
treatment, (B) iMG cells on day 14 after monocytes treated with GM-CSF and IL-34, and (C) iMacs on day 5 after monocytes treated with GM-CSF.
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previously (Ohgidani et al., 2014; Sellgren et al., 2017). Untreated
monocytes showed a round morphology (Figure 1A). Upon
induction, the microglia-like cells started to grow branches on
day 5 (Supplementary Figure 1A). On day 10–14, they displayed
a typical morphology of resting ramified microglia with a
small cell soma and multiple branching processes (Figure 1B).
It was worth noting that the iMG cells could survive up
to 36 days when culture media was replaced every 3 or 4
days (Supplementary Figure 1B). Formacrophage induction, we
treated monocytes with GM-CSF for 5–7 days. On day 5, the
phase-contrast image showed the typical “fried-egg” shape of
macrophages with enlarged circular cell body (Figure 1C), which
was consistent with the previous description (Jin and Kruth,
2016).
Microglia-Specific Markers Expressed by
iMG Cells
As a specialized macrophage, microglia share many common
markers with macrophages, including Iba1 (Ionized calcium
binding adapter molecule 1), transcription factor PU.1,
chemokine receptor CX3CR1, and TREM2. On the other
hand, transmembrane protein 119 (TMEM119) and purinergic
receptor P2RY12 are considered unique markers for microglia
but are absent on macrophages (Satoh et al., 2016; Zhu et al.,
2017). In this study, we used both myeloid and microglia-specific
markers to verify the specificity of iMG cells. As expected,
TMEM119 and P2RY12 markers were expressed by iMG cells,
as shown in Figure 2A(b,d). These two markers were absent on
iMacs, as shown in Figure 2A(a,c). These results were consistent
with recent studies from two different groups (Muffat et al., 2016;
Douvaras et al., 2017), where hiPSC-derived microglia-like cells
also expressed TMEM119 and P2RY12 markers. On the other
hand, myeloid lineage markers, such as Iba1, PU.1, CX3CR1,
and TREM2, were all expressed by both iMG cells s shown in
Figure 2B(b,d,f,h) and iMacs as shown in Figure 2B(a,c,e,g). The
results from immunocytochemistry indicated that monocytes-
derived iMG cells and iMacs expressed common markers of
myeloid lineage but only iMG cells expressed microglia-specific
markers, TMEM119 and P2RY12. Therefore, TMEM119 and
P2RY12 can be used as markers to distinguish iMG cells from
monocyte-derived macrophages.
FIGURE 2 | iMG cells expressed microglia-specific markers (TMEM119 and P2RY12) and other myeloid-specific markers. The expression of surface markers on the
iMG cells and iMacs were performed by immunocytochemistry. Peripheral monocytes were incubated with GM-CSF (iMacs) for 5–7 days or cocktail of GM-CSF and
IL-34 (iMG cells) for 10–14 days. Representative images of iMacs and iMG cells were shown. (A) iMG cells expressed unique microglial markers TMEM119 (b) and
P2RY12 (d), which were absent from iMacs (a,c). (B) Myeloid lineage markers were expressed on both iMacs and iMG cells, such as Iba1 (a,b), PU.1 (c,d), CX3CR1
(e,f), and TREM2 (g,h). Images were captured at 40× with a scale representing 20µm, where P2RY12, CX3CR1, and TREM2 were stained green, TMEM119, Iba1,
and PU.1 were stained red. Cellular nuclei were stained blue with DAPI.
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FIGURE 3 | iMG cells phagocytosed fibrillary Aβ42. Confocal imaging and flow cytometry analysis of iMG cells were incubated with human HiLyte
TM Fluor 488-labeled
Aβ42 proteins. Phagocytosis activity was measured after 4 h incubation. (A) Representative confocal images were shown where controls cells were panel a (a1–a4)
and iMG cells with phagocytosed fAβ42 were panel b (b1–b4). Images were captured at 100× with a scale representing 10µm. fAβ42 and Iba1were stained green and
red, respectively. Nuclei were stained blue with DAPI. Merged images of all three channels were shown in a4 and b4. Merged image (b4) indicated Aβ42 proteins were
present within the cytoplasm of iMG cells. (B) The Aβ42 protein uptake was quantified by flow cytometry. Representative image of three experiments were shown,
where the blue graph was for control and red for iMG cells with engulfed fAβ42. (C) Percentage of cells with engulfed fAβ42 as measured by flow cytometry. The result
was from three independent experiments, and the error bars represented ± SD. *p ≤ 0.05 was considered as significant.
Phagocytosis Assay in iMG Cells
Phagocytosis is one of the most fundamental functions of
microglia, and it maintains CNS homeostasis (Fu et al., 2014).
Aβ42 are found abundantly in the AD brain, and fibrillary Aβ42
(fAβ42) is closely linked to AD pathogenesis (Crouch et al., 2008).
To determine the phagocytic capacity of iMG cells, we used fAβ42
tomimic the physiological condition of AD patients. Considering
that Iba1 is a microglia/macrophage-specific calcium-binding
protein that participates in membrane ruffling and phagocytosis
in activated-microglia, we co-stained the iMG cells with anti-
Iba1 antibody to ensure that fAβ42 were physically engulfed
inside the cells. As a negative control, no green fluorescent
fAβ42 were detected inside iMG cells in Figure 3A(a1–a4), where
the iMG cells were not treated with fAβ42. However, green
fluorescent fAβ42 were detected inside iMG cells, along with
the red fluorescent Iba1 staining in the cytoplasm, as seen in
Figure 3A(b1–b4). The confocal images clearly indicated that
iMG cells could phagocytose extracellular protein aggregates
from their surroundings. Next, we quantitated the percentage of
iMG cells with phagocytic activity by flow cytometry. Our result
showed that 44.73 ± 4.20% of iMG cells had fluorescent-labeled
fAβ42 (Figures 3B,C). Together, we showed that iMG cells indeed
could engulf exogenous proteins (fAβ42), implicating potential
application for AD study.With the flow cytometry for fluorescent
fAβ42 detection, our model has the potential to measure and
compare the microglial capacity between different groups, such
as between AD patients and controls.
M1 and M2 Phenotypic Changes in iMG
Cells During Polarization
Upon stimulation, microglia have the capacity to polarize
toward a spectrum of activation states ranging from M1 (pro-
inflammatory state) to M2 (anti-inflammatory state) (Tang and
Le, 2016). Phenotypic changes, including morphology, gene
expression, and cytokine release, occur during the polarization
(Peng et al., 2017). LPS is a well-known agent for M1
polarization, whereas IL-4 is often used for M2 polarization.
With LPS treatment, we noticed that M1 activated-iMG cells had
undergone morphological changes showing super-ramified long
branches (Figure 4B) compared to iMG cells without activation
(Figure 4A). On the other hand, iMG cells activated by IL-
4 treatment, exhibited an amoeboid shape, having a round
cytoplasm with fewer short branches (Figure 4C). These changes
were consistent with previous reports that microglia in M1-state
encompassed long processes with ramified shapes, and microglia
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in M2-state possessed short and thick processes (Lecours et al.,
2018; Geirsdottir et al., 2019).
We then tested whether M1 and M2 activated-microglia
expressed specific activation markers during the polarization.
TNF-α, CD86, CD16/32, and inducible nitric oxide (iNOS)
are commonly used as markers for M1 activated-microglia
(David and Kroner, 2011; Kobayashi et al., 2013). M2 activated-
microglia, however, often shows upregulation of CD163 or
CD206 (Cherry et al., 2014). In this study, we used the mRNA
expression levels of TNF-α and CD206 as signals for M1 and M2
activation, respectively. As expected, TNF-α mRNA expression
in iMG cells was significantly upregulated (12.20 ± 4.00 folds,
p < 0.005) when treated with LPS (Figure 4D). IL-4 treatment
did not change TNF-α mRNA levels in the iMG cells. Similarly,
CD206 mRNA expression was increased (2.41 ± 0.90 folds, p <
0.005) in iMG cells with IL-4 treatment (Figure 4E). LPS did not
change CD206 mRNA expression in iMG cells. The upregulation
for M1 or M2 specific genes and the typical morphological
changes demonstrated that iMG cells were highly plastic that they
were able to polarize into M1 or M2 state when responding to
exogenous stimulants (LPS or IL-4).
iMG Cells Closely Clustered With
Brain-Resident Microglia From RNA-seq
Analyses
We showed that iMG cells were similar with primary microglia
in morphology, specific markers, and functions. Now we asked
whether the iMG cells were similar to human brain-resident
microglia or hiPSC-inducedmicroglia from their gene expression
profile. For this purpose, we did RNA-seq for monocytes,
iMacs, and iMG cells. We also downloaded RNA-seq data
from Muffat et al. (2016), Gosselin et al. (2017), and Grubman
et al. (2020) for comparison (see Supplementary Table 3 for
more details about the datasets). We first conducted PCA
analyses for the whole-genome RNA-seq data for the three
groups of cells (monocytes, iMacs, and iMG cells) in our
induction system. Indeed, we identified three distinctive groups
for monocytes, iMacs, and iMG cells from the PCA plot
(Supplementary Figure 2), suggesting that the monocytes were
successfully differentiated into two other cell types (iMacs or iMG
cells) with different induction cytokines. To further determine
whether iMG cells resembled the brain-resident microglia or
hiPSC-induced microglia, we obtained gene expression data
from the above mentioned studies (Muffat et al., 2016; Gosselin
et al., 2017; Grubman et al., 2020). We then conducted
MDS analyses with normalized data. As shown in PCA plot
(Supplementary Figure 2), the MDS plot clearly showed that
the three groups of cells were well-separated in our studies
(Figure 5A). hiPSC-induced microglia from Muffat et al. and
Grubman et al.’s groups, while clustered by each study,
there were some distances between the studies. The resident
microglia and monocytes from the Gosselin et al.’s study
were scattered. This might be due to the different micro-
environment where these cells resided. Overall, iMG cells from
our study were the closest to the hiPSC-induced microglia
and the resident microglia from human brain, but they were
separated from monocytes. This confirmed that our iMG cells
did have the features of microglia when mRNA expression data
were compared.
We further performed 2D hierarchical clustering analysis
of the RNA-seq data from our iMG cells against previously
published RNA-seq data from human brain-resident microglia
(Ref_hMG) (Gosselin et al., 2017). As mentioned above, a total
of 914 microglial signature genes were included in this study
(Supplementary Table 2). After matching with our RNA-seq
profiles, we obtained an overlap of 805 genes shared between
iMG cells and Ref_hMG, among which 312 were consistent
between the two groups, as compared with fold changes with
monocytes. Based on further differential analysis across iMG
cells and monocytes with criteria |FC| (fold changes) ≥1.2, p
≤ 0.001, and average expression ≥5, we generated top 201
microglial differentially expressed genes. With RNA profiles
from iMG cells and Ref_hMG, we attempted to evaluate how
close the induced-microglia resembled human brain microglia at
RNA expression levels. With the top 201 microglial differential
genes, we conducted 2D hierarchical clustering analysis. Our
data showed that iMG cells clustered closely with Ref_hMG,
whereas monocytes from our experiments clustered closely
with Ref_Monocytes (Figure 5B). We also noticed that iMG
cells and iMacs were clustered closely to each other. These
results demonstrated that monocytes treated with IL-34 and
GM-CSF underwent significant changes in gene regulation and
differentiated toward human microglia-like cells. The expression
pattern of surface markers were consistent with a previous
report (Ohgidani et al., 2014; Sellgren et al., 2017). As compared
to monocytes, the iMG cells and iMacs were clustered more
closely, reflecting that iMG cells were specialized macrophages
in the brain.
Venn Analysis and Differential Analysis
Across iMG Cells, iMacs, and Monocytes
To comprehend the differences between monocytes, iMacs, and
iMG cells, we performed Venn analysis across the three groups.
Unique genes to each cell type and shared genes across three
or two cell types were shown in the Venn diagram (Figure 6A),
where 350 genes were uniquely expressed in iMG cells. We also
found that 409 genes and 859 genes were specifically expressed
in iMacs and monocytes, respectively. 15,801 genes were shared
across all three groups.
Gene enrichment analysis was performed with unique genes
in each group. Our results showed that the unique genes from
iMG cells were enriched in the pathways involving in the
regulation of synaptic vesicle fusion and ion transport, and
TNFs bind their physiological receptors, which aligned with
microglial function in regard to their interaction with neurons
and response to the environment (Figure 6B). The unique
genes from monocytes were enriched in innate immune-related
pathways, such as complement activation, phagocytosis, and
cytokine-cytokine receptor interaction (Figure 6C). Surprisingly,
409 unique genes from iMacs were not enriched in many
pathways, but only associated with the transport of small
molecules pathway (Figure 6D).
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FIGURE 4 | In vitro activation and polarization of iMG cells. The morphology of iMG cells was captured after stimulation with LPS or IL-4 for 24 h. (A) Control iMG cells
without any treatment, (B) iMG cells stimulated with 10µg/ml LPS showing hyper-ramification as indicated with arrows, (C) iMG cells stimulated with 20 ng/ml IL-4
showing ameboid structure as indicated with arrows. Changes in gene expression were analyzed by qRT-PCR showed (D) increased TNF-α levels in LPS-stimulated
iMG cells and (E) increased CD206 levels in IL-4-stimulated iMG cells. The experiments were all repeated at least three times. Data were represented as a mean ±
SD. Significance between groups were determined by ANOVA test, where ** denoted p < 0.005.
The differences in gene expression between iMG cells and
monocytes were also shown in the volcano plot, where significant
genes were those that passed the FDR (p < 1 × 10−16) and
|log2FC|> 2, as indicated in red (Figure 6E). Interestingly,APOE
and TREM2, two of the most important risk genes for AD, were
both significantly upregulated (Figure 6E), with p= 7.09× 10−31
and 2.35 × 10−40, respectively. Differentially expressed genes
(DEGs) between iMG cells and monocytes, or Ref_hMG and
monocytes, were shown in Supplementary Tables 4, 5.
Genes in the complement system are highly expressed in
microglia and play an important role in synaptic pruning
that may underlie the mechanisms of brain diseases, such as
schizophrenia and AD. Ryan et al.’s group recently reported
a microglia-like model generated from human monocytes in
the presence of polarizing cytokines (IL-34, GM-CSF, M-CSF,
NGF-β, and CCL2). We wanted to compare some of the
microglia-specific genes from those of previous studies. Our
data showed that genes involved in the synaptic remodeling,
such as complement factors C1QA, C1QB, C1QC, C2, C3, C9,
C59, and SERPING1, were highly expressed in our iMG cells,
consistent with Gosselin et al.’s report and Ryan et al.’s report
(Figure 6F) (Gosselin et al., 2017; Ryan et al., 2017). Among
those, C1QA, C1QB, C1QC, and C2 were only upregulated in
iMG cells but not iMacs. We also found that more than half
of genes (19) in iMG cells overlapped with 37 genes from
MDMi (human monocyte-derived microglia-like cells) from
Ryan et al.’s group (Ryan et al., 2017) (Supplementary Table 6).
Interestingly, four genes mentioned as being microglia-specific
in mice in Ryan et al.’s report, TGFβR1, PROS1, P2RX7,
and C1QB, were consistently upregulated in our iMG cells
(Supplementary Figure 3). As mentioned above, two of the most
important risk genes for AD, APOE and TREM2, were also
significantly upregulated (Supplementary Figure 3).
DISCUSSION
Microglia are essential for the maintenance of normal brain
functions. Massive evidence shows that microglial dysfunction
contributes to neurodevelopmental and neurodegenerative
processes. Over the past 100 years of research on microglia,
advances have been made in understanding microglial plasticity,
transcriptional diversity, function-related signaling pathways,
and stem-cell-based microglial induction systems (Umpierre
and Wu, 2020). Technical developments also have advanced
scientists to explore human microglia-like cellular models from
human blood monocytes (Ohgidani et al., 2014; Ryan et al.,
2017; Sellgren et al., 2019), or hiPSC (Muffat et al., 2016; Abud
et al., 2017; Douvaras et al., 2017; Haenseler et al., 2017; Pandya
et al., 2017; Svoboda et al., 2019). In vitro differentiation from
hiPSC to microglia is challenging as the reprogramming process
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FIGURE 5 | Multidimensional scaling analysis (MDS) and 2D hierarchical clustering from RNA-seq profile of iMG cells. (A) MDS analysis for multiple RNA-seq
datasets, including iMG cells, iMacs, and monocytes from our study, hiPSC-induced microglia (iMGL) and fetal microglia (FML) from Muffat et al.’s study, iMGL from
Grubman et al.’s study, and human brain microglia (MGL) and monocytes from Gosselin et al.’s study. (B) 2D hierarchical clustering with 201 top differentially
expressed genes from our study and Gosselin et al.’s study, where Ref_hMG and Ref_Mono were human brain-resident microglia and monocytes from Gosselin
et al.’s study (Gosselin et al., 2017). iMG cells were induced microglia-like cells from monocytes and iMacs were induced macrophages from monocytes in our study.
is time-consuming (Liang and Zhang, 2013). It is essential to
establish a more efficient microglial model closely resembling
the human microglial phenotypic and functional features. It
is also crucial to build the model from a relatively easy and
non-invasive sample collection process. With modification from
Ohgidani et al.’s report (Ohgidani et al., 2014), we generated
and validated the microglia-like model from human peripheral
monocytes. Consistent with the previous studies (Ohgidani et al.,
2014; Sellgren et al., 2017), our data showed that iMG cells
had the typical ramified morphology as resting microglia in
the brain and expressed microglia-specific surface markers, such
as TMEM119 and P2RY12. On the contrary, iMacs with GM-
CSF treatment showed a typical “fried-egg” morphology without
TMEM119 and P2RY12 expression. Another group has used a
complex cocktail (IL-34, GM-CSF, M-CSF, NGF-β, and CCL2)
for microglia induction (MDMi) (Ryan et al., 2017). While
comparing microglial genes, iMG cells and MDMi shared more
than half of those microglia-specific genes and 4 specific genes
were significantly upregulated in iMG cells, MDMi, and human
microglia. These results demonstrated that microglia induced
from monocytes with different inductions shared some common
microglia features, though, at this stage it is not clear what
the difference is between the two inductions. We know that
differentiation from hiPSC to microglia-like cells usually takes
around 40 days (Muffat et al., 2016; Grubman et al., 2020). In this
study, our induction frommonocyte to microglia took<2 weeks.
In addition, blood collection from patients is widely accepted for
clinical research. Thus, there is no doubt that our model will
provide a more feasible and efficient approach to study microglial
functions in clinical trials.
As mentioned above, microglia are professional phagocytic
cells of the brain that remove apoptotic or necrotic cells (Green
et al., 2016) and eliminate unfolded proteins, such as Aβ (Daniel
Lee and Landreth, 2010). To evaluate the phagocytic capacity
of iMG cells, we chose fibrillary Aβ as an exogenous proteins
to best mimic the physiological condition for phagocytosis in
most AD patients. Nonetheless, it should be noted that different
Aβ preparation methods can affect Aβ aggregation kinetics and
structures (Yates and Legleiter, 2014; Nirmalraj et al., 2020).
It is still not clear under what circumstances various types of
Aβ are formed physiologically inside the brain (Chen et al.,
2017). Microglia are believed to initially clear Aβ deposits at a
preclinical stage of AD. With the progress of AD, they somehow
lose their ability to clear Aβ as they are activated to a pro-
inflammatory state where cytokines, chemokines, and reactive
oxygen species (ROS) are released (Hale et al., 2008). To our
knowledge, we are the first to show the phagocytic capacity of
monocyte-derived microglia engulfing exogenous Aβ proteins.
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FIGURE 6 | Venn and differential expression analysis and enrichment analysis. (A) Venn diagram of genes expressed by iMG cells, iMacs, and monocytes (defined by
the mean of the normalized counts >10). Blue: Monocytes; Red: iMacs; Green: iMG cells. Enrichment analysis with the unique genes expressed in iMG cells (B),
monocytes (C), and iMacs (D), ranked by pathway p-value. (E) Volcano plot depicting differentially expressed genes in iMG cells against monocytes. The dashed line
indicated p < 1 × 10−16 (horizontal line) and |log2FC| >2 (Vertical line). Two well-known AD risk genes, APOE and TREM2, were both upregulated in iMG cells as
labeled in the Volcano plot. (F) Relative expression of significant genes (C1QA, C1QB, C1QC, C2, C3, C9, CD59, and SEPRING1) from the complement system in
iMG cells vs. monocytes, and iMacs and. p values were obtained from differential expression analysis DESeq2 v1.28.1, where **** denotes p < 0.001.
This is crucial as utilizing this microglial model will help us
to understand the underlying mechanism by which microglia
remove Aβ proteins under physiological condition and how they
lose the ability of Aβ clearance during pathological condition.
Our cellular model provides a feasible tool to measure microglial
function of phagocytosis. With different compounds or with
genetic engineering approaches, iMG cells can be used to evaluate
their effects on removing internal or external proteins, including
Aβ proteins in AD clinical trials. As a result, this model would
offer a prompt monitor system for microglial functions at the
cellular level, which facilitates new drug discovery or disease-
modified treatment.
Microglia are highly plastic; they can be activated into the
pro-inflammatory (M1) state or into the anti-inflammatory
(M2) state in response to various stimuli. Such microglia
remodeling is critical for microglial phagocytosis, synaptic
modifications, and neuroinflammatory responses and normal
brain functioning. As an example, pro-inflammatory M1
microglia are usually dominant in AD and schizophrenia
pathology. With morphological changes and specific polarization
markers upregulation, our data demonstrated that iMG cells
could be transformed into M1 state with LPS stimulation or
M2 state with IL-4 stimulation. Thus, iMG cells provide a
human microglial cellular model that can be used to study the
mechanisms underlying the microglial polarization (Svoboda
et al., 2019). Future studies with the iMG cells model for
comprehensive comparison between patients and healthy
controls have the potential to identify the microglia-relevant
mechanisms associated with AD, schizophrenia, and
other diseases.
In this study, we also conducted a comprehensive gene
expression profiling of iMG cells and compared it with expression
data from brain-derived microglia. From cluster analysis, our
data indicated that iMG cells were closely clustered with brain-
resident microglia or hiPSC-induced microglia. Interestingly, the
unique genes from iMG cells were enriched in pathways involved
in the regulation of synaptic vesicle and ion transport, and
synapse organization. Multiple genes in the complement system,
C1QA, C1QB, C1QC, C2, C3, C9, CD59, and SEPRING1, were
also highly up-regulated. This confirms that microglia-specific
genes had been remodeled during the differentiation from
monocytes to iMG cells and possess specialized brain functions
(e.g., synaptic remodeling). Excessive evidence has shown that
microglial dysfunction contributes to synaptic abnormalities and
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cognitive decline, which are often seen in neurodevelopmental
and neurodegenerative disorders. Indeed, Sellgren et al. recently
applied the model to investigate schizophrenia. They found that
iMG cells derived from patients with schizophrenia eliminated
more synapses than those from healthy controls (Sellgren et al.,
2019). Sellgren et al. demonstrated that iMG cells would be
a good model to study schizophrenia. Several other groups
have successfully applied this iMG model or similar model to
study the microglial functions in different disorders, including
bipolar disorder, fibromyalgia, and schizophrenia (Ohgidani
et al., 2017a,b; Ormel et al., 2020). In this study, we demonstrated
that the iMG cellular model would also be a good model
for studying cellular changes and gene regulation during the
development of AD, mainly the phagocytosis of fAβ42 and the
gene expression profiles. The two genes TREM2 and APOE are
widely accepted as high risk genes for non-familial AD (Shi and
Holtzman, 2018; Wolfe et al., 2018). Our RNA expression data
indicated the two genes were significantly upregulated in iMG
cells as compared to monocytes.
Our iMG cellular model has some limitations. In spite
of the promising results, the model might still not fully
recapitulate the microglial phenotypes from the human brain.
We understand this limitation and acknowledge that this
is a challenge to any surrogate cellular model in the field.
Nevertheless, our study showed that the iMG cellular model had
extensive human microglial features at phenotypic, functional,
and gene expression levels that warrant its application in
schizophrenia and AD studies. Other limitations include subject
to subject variations, cell viability during induction, and high
sensitivity to culture microenvironments. We acknowledge that
these limitations may create some variations across batches
of experiments. However, the results from our in vitro iMG
cells were highly compatible and consistent with studies from
other groups. Therefore, our model derived from patients
with psychiatric diseases or neurodegenerative diseases would
be a good alternative for the study of gene regulations
and characterization of disease-related microglial phenotypes,
provided that each experiment has age- and sex-matched
controls. Furthermore, our study indicated that this microglial
model can be extended to study the molecular mechanisms
underlying synapse remodeling during brain development and
neurodegeneration. Finally, this iMG model can also be used for
high throughput studies for the discovery of new biomarkers or
new drugs.
Overall, our findings confirmed that iMG cellular model
exhibited cellular and molecular characteristics that were
similar to human brain-resident microglia. Functional studies
of such patient-specific microglial model will facilitate a better
understanding of neuroinflammatory processes in psychiatric
and neurodegenerative diseases. We were the first to validate
the iMG cellular model with comprehensive RNA profile,
although we were not the first study to generate this human
monocyte-derived microglial model. Additionally, this study
investigated the plasticity of the induced-microglia with two
distinct polarization states. Therefore, the present study provides
valuable data regarding the application of this model to study
the pathogenesis of psychiatric and neurological disorders,
including schizophrenia and AD, two diseases with cognitive
deficits closely linking to microglial activation, synaptic pruning,
and neuroinflammation. Further studies using this cellular
model derived from patient samples are required to confirm
our findings.
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Supplementary Figure 1 | The morphology of iMG cells on days 5 and 36. (A)
Branched cells were observed on day 5 after the treatment with IL-34 and
GM-CSF. (B) The iMG cells survived up to 36 days.
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Supplementary Figure 2 | Principal component analysis (PCA) from RNA-seq
profile. PCA plot of monocytes, iMacs, and iMG cells from whole-genome
RNA-seq profile.
Supplementary Figure 3 | Upregulation of microglia-specific genes and AD risk
genes in iMG Cells. Four genes mentioned as being mice microglia-specific in
Ryan et al.’s report, TGFβR1, PROS1, P2RX7, and C1QB, were consistently
upregulated in our iMG cells. Two AD-risk genes, APOE and TREM2, were
significantly upregulated in iMG cells. P-values were obtained from differential
expression analysis DESeq2 v1.28.1., where ∗∗∗∗ denotes p < 0.001, ∗∗∗ denotes
p < 0.005.
Supplementary Table 1 | Sample information for RNA-seq profiling.
Supplementary Table 2 | Microglia signature genes in this study.
Supplementary Table 3 | Datasets for MDS analysis in this study.
Supplementary Table 4 | DEGs between iMG cells and monocytes.
Supplementary Table 5 | DEGs between Ref_hMG and monocytes.
Supplementary Table 6 | Overlapping genes between iMG cells and Ryan et al.’s
data or Ref_hMG and Ryan et al.’s data.
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